SAMHD1 and acute myeloid leukemia: In SAMHD1‐proficient AML, ara‐C treatment had no effect on survival as compared to PBS treatment, but ara‐C significantly prolonged survival in SAMHD1‐deficient AML mice, resulting in a median survival of 68 days (P = 0.0018), consistent with our previously published results (Herold et al, 2017a,b,c).